

1 **Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among**
2 **hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong**
3 **Kong's Omicron BA.2 wave: an observational study**

4
5 Carlos K.H. Wong^{1,2,3} PhD, Ivan C.H. Au¹ BSc, Kristy T.K. Lau¹ MSc, Eric H.Y. Lau^{3,4}
6 PhD, Benjamin J. Cowling^{3,4*} PhD, Gabriel M. Leung^{3,4*} M.D

7 Affiliation

8 1 Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of
9 Hong Kong, Hong Kong SAR, China

10 2 Department of Family Medicine and Primary Care, LKS Faculty of Medicine, The
11 University of Hong Kong, Hong Kong SAR, China

12 3 Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology
13 Park, Hong Kong SAR, China

14 4 WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
15 Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,
16 China

17 * Full professors

18 **Corresponding authors:**

19 Carlos King Ho Wong (carlosho@hku.hk)

20 Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of
21 Hong Kong, 26 Sassoon Road, Pokfulam, Hong Kong SAR, China

22 Benjamin John Cowling (bcowling@hku.hk)

23 World Health Organization Collaborating Center for Infectious Disease Epidemiology and
24 Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, 7
25 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region, China

26
27 **Running Title:** Effectiveness of molnupiravir and nirmatrelvir/ritonavir

28 **Word count (Abstract):** 334

29 **Word count (Main text):** 3,871

1 **Summary**

2

3 **Background**

4 Effectiveness of oral antivirals in mild-to-moderate COVID-19 patients is urgently needed.

5 This retrospective cohort study aims to evaluate the clinical and virologic outcomes

6 associated with molnupiravir and nirmatrelvir/ritonavir use in COVID-19 patients during a

7 pandemic wave dominated by the Omicron BA.2 subvariant.

8

9 **Methods**

10 We analyzed data from a territory-wide retrospective cohort of hospitalized patients with

11 confirmed diagnosis of SARS-CoV-2 infection from 26th February 2022 to 26th April 2022

12 in Hong Kong. Oral antiviral users were matched with controls using propensity-score

13 matching in a ratio of 1:1. Study outcomes were all-cause mortality, a composite outcome of

14 disease progression (all-cause mortality, initiation of invasive mechanical ventilation [IMV],

15 intensive care unit admission, or the need for oxygen therapy) and their individual outcomes,

16 and time to achieving lower viral burden of cycle threshold (Ct) value ≥ 30 cycles. Hazard

17 ratios (HR) of event outcomes were estimated using Cox regression models.

18

19 **Results**

20 Among 40,776 hospitalized patients with SARS-CoV-2 infection over a mean follow-up of

21 41.3 days with 925,713 person-days, this study included 1,856 molnupiravir users, 890

22 nirmatrelvir/ritonavir users and 2,746 control patients not initially requiring oxygen therapy

23 at baseline after propensity-score matching. Oral antiviral use was associated with

24 significantly lower risks of all-cause mortality (molnupiravir: HR=0.48, 95%CI=0.40-0.59,

25 $p < 0.0001$; nirmatrelvir/ritonavir: HR=0.34, 95%CI=0.23-0.50, $p < 0.0001$), the composite

26 outcome of disease progression (molnupiravir: HR=0.60, 95%CI=0.52-0.69, $p < 0.0001$;

27 nirmatrelvir/ritonavir: HR=0.57, 95%CI=0.45-0.72, $p < 0.0001$), and the need for oxygen

28 therapy (molnupiravir: HR=0.69, 95%CI=0.57-0.83, $p = 0.00011$; nirmatrelvir/ritonavir:

29 HR=0.73, 95%CI=0.54-0.97, $p = 0.032$) than non-use. Time to achieving lower viral burden

30 was significantly shorter among oral antiviral users than matched controls (molnupiravir:

31 HR=1.38, 95%CI=1.15-1.64, $p = 0.0046$; nirmatrelvir/ritonavir: HR=1.38, 95%CI=1.07-1.78,

32 $p = 0.013$).

33

34 **Conclusions**

1 Against Omicron BA.2, initiation of novel oral antiviral treatment in hospitalized patients not
2 requiring any oxygen therapy was associated with lower risks of all-cause mortality and
3 disease progression, in addition to achieving low viral burden faster. Our findings support the
4 early use of oral antivirals in COVID-19 patients who do not require supplemental oxygen on
5 admission.

6

7 **Funding:** Health and Medical Research Fund, Food and Health Bureau, Government of the
8 Hong Kong SAR

1 **Research in context**

2

3 **Evidence before this study**

4 The medical and research community are actively exploring the use of oral antivirals in
5 COVID-19 patients to lower their risks of hospitalization and death, and to reduce the burden
6 on healthcare systems. We searched Scopus and PubMed for studies until 13th May 2022
7 using the search terms “SARS-CoV-2 OR COVID-19” AND “molnupiravir OR Lagevrio OR
8 EIDD-2801” OR “nirmatrelvir OR Paxlovid OR PF-07321332”. Major studies examining the
9 safety and efficacy of molnupiravir include MOVE-IN and MOVE-OUT trials conducted in
10 hospitalized and non-hospitalized COVID-19 patients, respectively. Clinical evidence for the
11 use of ritonavir-boosted nirmatrelvir came from the EPIC-HR trial conducted among non-
12 hospitalized adults with COVID-19. While no clinical benefits have been observed with
13 molnupiravir use in the inpatient setting among patients with moderate-to-severe COVID-19,
14 early initiation of molnupiravir or nirmatrelvir/ritonavir within 5 days of symptom onset in
15 non-hospitalized patients with mild-to-moderate COVID-19 and risk factors for progression
16 to severe disease has been associated with relative risk reduction of hospitalization or death
17 by 30% and 88%, respectively. Notably, these clinical trials were conducted prior to the
18 prevalence of Omicron variant, and the efficacy of oral antivirals against this current variant
19 of concern can only be inferred from experimental evidence to date. Real-world evidence of
20 oral antiviral use in patients with SARS-CoV-2 infection of Omicron variant is lacking.

21

22 **Added value of this study**

23 To the best of our knowledge, this is the first real-world study exploring the inpatient use of
24 oral antivirals during a pandemic wave dominated by SARS-CoV-2 Omicron variant. We
25 conducted a territory-wide, retrospective cohort study to examine the effectiveness of
26 molnupiravir and nirmatrelvir/ritonavir in COVID-19 patients who did not require
27 supplemental oxygen on admission in Hong Kong. Early initiation of oral antivirals within 2
28 days of admission was associated with significantly lower risks of all-cause mortality and
29 disease progression, in addition to achieving low viral burden faster than their respective
30 matched controls. Oral antiviral use was also associated with a reduced need for oxygen
31 therapy than non-use.

1

2 **Implications of all the available evidence**

3 Current guidelines are now prioritizing the distribution of oral antivirals to those who do not
4 require supplemental oxygen, but who are at the highest risk of disease progression. Our
5 study cohort reflected such prescription pattern in real-world clinical practice, consisting of
6 mostly the elderly with multiple pre-existing comorbidities and who had not been fully
7 vaccinated. The antiviral effect and mortality benefit observed in this patient cohort support
8 the use of oral antivirals in COVID-19 patients who do not require supplemental oxygen on
9 admission during a pandemic wave of Omicron variant. Ongoing research will inform the
10 safety and effectiveness of oral antivirals in specific patient populations (by vaccination
11 status and viral variants), drug combinations, and different healthcare settings.

1 **Manuscript text**

2
3 **Introduction**

4
5 In the midst of the coronavirus disease 2019 (COVID-19) pandemic, various drugs have been
6 repurposed or developed for treating patients with SARS-CoV-2 infection. In December 2021,
7 molnupiravir (Lagevrio) and ritonavir-boosted nirmatrelvir (Paxlovid) are two oral antivirals
8 that have been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug
9 Administration (FDA) for the treatment of non-hospitalized patients with mild-to-moderate
10 COVID-19, who are at risk of progression to severe disease, so as to reduce the burden on
11 healthcare systems by lowering their risk of hospitalization or death.^{1,2}

12
13 While both molnupiravir and nirmatrelvir/ritonavir are indicated for non-hospitalized patients
14 with mild-to-moderate COVID-19 within 5 days of symptom onset should they be at risk of
15 progression to severe disease, current guidelines give priority to nirmatrelvir/ritonavir
16 (relative risk reduction by 88%) and another antiviral remdesivir (by 87%) that have
17 demonstrated higher efficacy than molnupiravir (by 30%) in reducing hospitalization or death
18 among COVID-19 patients not requiring hospitalization or supplemental oxygen.¹⁻⁴ Notably,
19 several concerns and research gaps remain in the use of the two oral antivirals, for instance, if
20 initiation in asymptomatic COVID-19 patients is appropriate, the lack of clinical data in
21 treating patients infected with specific VOC, and their safety and efficacy in vaccinated
22 individuals with breakthrough infections.⁵⁻⁷ Furthermore, efficacy of molnupiravir as
23 illustrated in the MOVE-OUT trial has been questioned in light of its premature termination,
24 imbalances in risk factors and COVID-19 severity of patients at baseline, results with
25 borderline statistical significance and of uncertain clinical significance, and discrepancies
26 between interim and full analyses that could not be fully explained by differences in patient
27 characteristics.⁸⁻¹⁰

28
29 Real-world evidence on the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
30 COVID-19 patients is urgently needed.¹¹ This retrospective cohort study aims to evaluate the
31 clinical and virologic outcomes associated with molnupiravir and nirmatrelvir/ritonavir use in
32 COVID-19 patients during a community epidemic dominated by the Omicron BA.2
33 subvariant. While both oral antivirals are now indicated for non-hospitalized COVID-19
34 patients who are at high risk of disease progression, the current analysis focuses on their

1 effectiveness in hospitalized patients with COVID-19 who do not initially require any oxygen
2 therapy on admission.

3

4 **Methods**

5

6 **Study Design**

7 A territory-wide, retrospective cohort study was used to examine the effectiveness of oral
8 antivirals (molnupiravir or nirmatrelvir/ritonavir) in hospitalized adult patients with COVID-
9 19 without oxygen therapy in the Hong Kong Special Administrative Region, China, during
10 the observation period from 26th February 2022 to 5th May 2022.

11

12 **Data Source and Study Population**

13 Electronic health records of patients with COVID-19 were retrieved from the Hospital
14 Authority (HA), a statutory provider of public inpatient services and primary public
15 outpatient services in Hong Kong. Electronic health records included demographics, date of
16 registered death, hospital admission, emergency department visits, diagnoses, prescription
17 and drug dispensing records, procedures, and laboratory tests. The HA linked the health
18 records and anonymized population-based vaccination records of individuals provided by the
19 Department of Health using unique identification numbers (Hong Kong Identity Card or
20 foreign passport number). The database has been widely used for high-quality studies to
21 evaluate the safety and effectiveness of drug treatments for COVID-19 at a population
22 level.^{12,13} For all-cause mortality, data were extracted and ascertained from the Hong Kong
23 Death Registry, which would allow us to capture any death events of patients occurring
24 beyond hospital discharge (outside the hospital setting). Our cohort comprised patients with
25 positive results of reverse transcription-polymerase chain reaction (RT-PCR) or rapid antigen
26 test who were admitted to isolation wards at local public hospitals from 26th February 2022
27 to 26th April 2022. Patients were eligible for inclusion if they had been admitted within 3
28 days of their COVID-19 diagnosis date, or if COVID-19 diagnosis was confirmed within 3
29 days of their admission date, so as to account for any potential time lag in the confirmation of
30 cases during an upsurge of patients with SARS-CoV-2 infection. The index date was defined
31 as the date of hospital admission (day 0). Patients who were admitted to hospital with
32 COVID-19 before 26th February 2022 (the date when molnupiravir first became locally
33 available), after 26th April 2022 (less than 1 week of follow-up), or beyond 5 days of
34 symptom onset, aged <18 years, or with oxygen support or mechanical ventilation on the

1 index date, were excluded. Patients with drug contraindications to nirmatrelvir/ritonavir (i.e.
2 use of amiodarone, apalutamide, lumacaftor/ivacaftor, ivosidenib, rifampicin, rifapentine,
3 carbamazepine, St John's Wort, primidone, phenobarbital, or phenytoin in the past 6 months
4 prior to the baseline),¹⁴ severe renal impairment² (eGFR <30mL/min/1.73m², dialysis, or
5 renal transplantation), or severe liver impairment² (cirrhosis, hepatocellular carcinoma, or
6 liver transplantation) at baseline were excluded from the current analysis to further mitigate
7 confounding by indication as much as possible, and restrict the sample to those who were as
8 equally eligible to receive either molnupiravir or nirmatrelvir/ritonavir treatment as possible.

9
10 This study was approved by the institutional review board of the University of Hong Kong /
11 Hospital Authority Hong Kong West Cluster (reference no. UW 20-493). Given the
12 extraordinary nature of the COVID-19 pandemic, individual patient-informed consent was
13 not required for this retrospective cohort study using anonymized data.

14 15 **Treatment Exposure and Follow-up Period**

16 Hospitalized patients with COVID-19 without oxygen therapy and receiving early (i)
17 molnupiravir or (ii) nirmatrelvir/ritonavir treatment at public hospitals during the observation
18 period were defined as (i) molnupiravir users and (ii) nirmatrelvir/ritonavir users, respectively.
19 As all public hospitals in Hong Kong are managed by the Hospital Authority, oral antivirals
20 were prescribed to COVID-19 patients as clinically appropriate based on the same set of
21 standard treatment protocols, and both oral antivirals were equally accessible across all public
22 hospitals during the study period (since 26th February 2022 for molnupiravir,¹⁵ and
23 nirmatrelvir/ritonavir was locally available since 16th March 2022¹⁶). We defined treatment
24 exposure period at 2 days within admission to mitigate potential immortal time bias between
25 treatment initiation and admission.¹⁷⁻²⁰ Controls were selected from the cohort of hospitalized
26 patients with COVID-19 without oxygen therapy who did not receive oral antivirals
27 (molnupiravir and/or nirmatrelvir/ritonavir) during the observation period, using the
28 propensity-score in a ratio of 1:1, and considering the time period of admission. Patients were
29 observed from the index date until registered death, the occurrence of outcome events,
30 crossover of oral antiviral treatment, or the end of the observation period (5th May 2022),
31 whichever came first.

32 33 **Outcomes**

1 The primary outcome of this study was all-cause mortality. Secondary outcomes were a
2 composite outcome of disease progression (all-cause mortality, initiation of invasive
3 mechanical ventilation [IMV], intensive care unit [ICU] admission, or the need for oxygen
4 therapy) and their individual outcomes, and time to achieving lower viral burden of cycle
5 threshold (Ct) value ≥ 30 cycles. Viral burden information at baseline might not be
6 immediately available for a minority of patients who were admitted based on positive rapid
7 antigen test; and quantitative viral burden was not assessed as a routine procedure, especially
8 during the peak of Omicron BA.2 epidemic when public hospitals were overwhelmed with
9 cases. Hospital length of stay (LOS) was also determined for discharged survivors. In
10 response to an upsurge of COVID-19 cases during the study period and the limited number of
11 hospital beds, the HA had revised their discharge criteria on 26th February 2022 to allow
12 patients hospitalized with COVID-19 to be discharged as soon as they were deemed clinically
13 stable by their attending physicians, and provided that their residential premises were suitable
14 for isolation or they would be accepted by community isolation facilities, where they would
15 continue their isolation until negative test results were obtained (on days 6 and 7 for fully
16 vaccinated individuals [with at least two doses]; and day 14 for those not fully vaccinated
17 [unvaccinated or vaccinated with only one dose]).²¹

18

19 Over the follow-up period, changes in the proportion of patients with the respective clinical
20 status (namely in-hospital death, on invasive mechanical ventilation, without invasive
21 mechanical ventilation, and discharged) were compared between oral antiviral and respective
22 control groups.

23

24 **Baseline Covariates**

25 Baseline covariates of patients included age, sex, regions, nursing home residents, symptom
26 onset date reported, date of hospital admission, nosocomial infection (defined as
27 hospitalization before COVID-19 diagnosis), time period of hospital admission, Charlson
28 Comorbidity Index (CCI), any previous SARS-CoV-2 infection (defined as a recorded
29 medical history of confirmed SARS-CoV-2 infection), COVID-19 vaccination status (fully
30 vaccinated as having at least two doses of Comirnaty or three doses of CoronaVac),
31 concomitant treatments initiated on the index date (antibiotics, dexamethasone and other
32 systemic steroids, interferon- β -1b, baricitinib, and tocilizumab), and laboratory parameters on
33 admission (Ct value, lactate dehydrogenase, C-reactive protein, and lymphocyte count).

34

1 **Statistical Analyses**

2 Propensity-score models conditional on the aforementioned baseline covariates without first-
3 order interactions in a logistic regression model was performed, and the propensity of
4 receiving each oral antiviral was estimated in an approach of caliper matching without
5 replacement, with a caliper width of 0.05. Missing laboratory parameters (Supplementary
6 Table 1, Appendix p.2) for oral antiviral users were imputed 20 times using other parameters
7 in the propensity-score model.²² We applied Rubin's rules to pool the treatment effects
8 estimated from the 20 independent imputed datasets.²³ We used the standardized mean
9 difference (SMD) to assess the balance of each baseline covariate between the groups before
10 and after propensity-score matching, with SMD greater than 0.1 indicating covariate
11 imbalance.²⁴

12

13 Hazard ratios (HR) with 95% confidence intervals (CI) of each outcome between oral
14 antiviral users and non-users were estimated using Cox regression models. Since there is no
15 evidence that the proportional-hazards assumption has been violated using Schoenfeld
16 residuals, we assumed the proportionality of the hazard ratios in primary analysis. A cluster-
17 robust sandwich variance-covariance estimator was used in all the Cox regression models to
18 account for the correlation within the propensity-score match. Analyses were conducted
19 among the following patient subgroups: age (≤ 65 or > 65 years), fully vaccinated or not,
20 region, study period (before or after 16th March 2022, the date since both oral antivirals were
21 available across public hospitals), and with and without symptom onset date reported.
22 Sensitivity analyses were performed by 1) including only patients with complete 28-day
23 follow-up (i.e. inclusion period from 26th February to 7th April 2022), and 2) using the
24 observed baseline characteristics without laboratory parameters (without multiple imputation)
25 for propensity-score model. We re-matched baseline covariates, and constructed a new
26 propensity score model for each subgroup and sensitivity analysis.

27

28 All statistical analyses were performed using Stata version 17 (StataCorp LP, College Station,
29 TX). All significance tests were 2-tailed, where P-value < 0.05 was considered statistically
30 significant.

31

32 **Role of the funder**

33 The funder had no role in the data collection, analysis, interpretation, writing of the
34 manuscript, and the decision to submit.

1

2 **Results**

3

4 In this territory-wide, retrospective cohort study, a total of 40,776 hospitalized patients with
5 confirmed diagnosis of SARS-CoV-2 infection over a mean follow-up of 41.3 days (standard
6 deviation: 18.7) with 925,713 person-days were identified from 26th February 2022 to 26th
7 April 2022. This study included 1,856 molnupiravir users, 890 nirmatrelvir/ritonavir users
8 and 2,746 control patients not initially requiring oxygen therapy at baseline after propensity-
9 score matching. (Figure 1). Baseline characteristics of oral antiviral and control groups before
10 matching are presented in Table 1. After 1:1 propensity-score matching, this analysis
11 included 1,856 molnupiravir users (with 1,856 matched controls) and 890
12 nirmatrelvir/ritonavir users (with 890 matched controls) with COVID-19 not initially
13 requiring any oxygen therapy at baseline. After matching, propensity score distribution of
14 oral antiviral and matched control groups were highly overlapping (Supplementary Figure 1,
15 Appendix p.13) while baseline characteristics of patients were balanced between oral
16 antiviral and matched control groups with all SMDs ≤ 0.1 (Table 1 and Supplementary Table
17 2, Appendix p.3). The median duration from symptom onset to molnupiravir initiation was 1
18 (interquartile range [IQR]: 1-3) day, and that from symptom onset to nirmatrelvir/ritonavir
19 initiation was 1 (IQR: 1-3) day. The proportion of molnupiravir who received molnupiravir
20 800mg twice daily for 5 days was 96.7% (1,795 of 1,856), while the proportion of
21 nirmatrelvir/ritonavir users who completed the 5-days regimen (nirmatrelvir 300mg with
22 ritonavir 100mg twice daily for 5 days) was 98.8% (880 of 890).

23

24 The crude incidence rate of all-cause mortality was 19.98 events per 10,000 person-days
25 among molnupiravir users (Table 2), and 10.28 events per 10,000 person-days among
26 nirmatrelvir/ritonavir users (Table 3). Oral antiviral use was associated with significantly
27 lower risks of all-cause mortality (molnupiravir: HR=0.48, 95%CI=0.40-0.59, $p < 0.0001$;
28 nirmatrelvir/ritonavir: HR=0.34, 95%CI=0.23-0.50, $p < 0.0001$) and the composite outcome of
29 disease progression (molnupiravir: HR=0.60, 95%CI=0.52-0.69, $p < 0.0001$;
30 nirmatrelvir/ritonavir: HR=0.57, 95%CI=0.45-0.72, $p < 0.0001$) than non-use, which was
31 consistently observed for a reduced need for oxygen therapy (molnupiravir: HR=0.69,
32 95%CI=0.57-0.83, $p = 0.00011$; nirmatrelvir/ritonavir: HR=0.73, 95%CI=0.54-0.97, $p = 0.032$)
33 (Tables 2 and 3, and Figure 2). Meanwhile, the relatively lower risks of IMV initiation
34 observed in oral antiviral users were not significantly different from their control counterparts

1 (molnupiravir: HR=0.42, 95%CI=0.17-1.01, p=0.052; nirmatrelvir/ritonavir: HR=0.97,
2 95%CI=0.31-3.03, p=0.96). Time to achieving lower viral burden was significantly shorter
3 among oral antiviral users than matched controls (molnupiravir: HR=1.38, 95%CI=1.15-1.64,
4 p=0.00046; nirmatrelvir/ritonavir: HR=1.38, 95%CI=1.07-1.79, p=0.013). There was a
5 significant increase in the Ct value between baseline and day 5-7 in molnupiravir group
6 (mean=6.67, 95%CI=5.91-7.43, p<0.0001), nirmatrelvir/ritonavir group (mean=7.25,
7 95%CI=5.93-8.56, p<0.0001), and control group (mean=3.93, 95%CI=3.57-4.28, p<0.0001).
8 Molnupiravir users (diff=2.50, 95%CI=1.34-3.66, p<0.0001) and nirmatrelvir/ritonavir users
9 (diff=2.86, 95%CI=0.96-4.76, p=0.0034) had larger increases in Ct value over the window of
10 5-7 days than their matched control groups, respectively. Amongst survivors, no significant
11 differences were observed for hospital LOS between nirmatrelvir/ritonavir users (N=858) and
12 matched controls (N=798), while a slightly shorter LOS was evident in molnupiravir users
13 (N=1,706) compared to their control counterparts (N=1,561) (diff: -0.68 day, 95%CI: -1.31
14 to -0.06, p=0.033). Results of subgroup and sensitivity analyses were generally in line with
15 those of the main analysis (Supplementary Tables 3 and 4, Appendix p.5-12, respectively),
16 except for a seemingly lack of significant benefits among younger patients (aged ≤65 years)
17 and those who had been fully vaccinated.

18
19 Since day-7 from baseline, the proportion of patients with in-hospital death was noticeably
20 higher in the control group than oral antiviral users (molnupiravir: 5.3% [98 of 1,856] vs 2.3%
21 [43 of 1,856]; nirmatrelvir/ritonavir: 3.6% [32 of 890] vs 1.3% [12 of 890]), which persisted
22 until day-28 of follow-up (molnupiravir: 14.9% [276 of 1,856] vs 7.5% [140 of 1,856];
23 nirmatrelvir/ritonavir: 9.3% [83 of 890] vs 3.5% [31 of 890]) (Figure 3). At day-28, the
24 proportion of patients discharged was higher among oral antiviral users than respective
25 matched controls (molnupiravir: 84.4% [1,566 of 1,856] vs 75.3% [1,398 of 1,856];
26 nirmatrelvir/ritonavir: 89.6% [797 of 890] vs 82.5% [734 of 890]).

27 28 **Discussion**

29
30 In this retrospective cohort of COVID-19 patients not requiring any supplemental oxygen on
31 admission, initiation of molnupiravir or nirmatrelvir/ritonavir was associated with
32 significantly lower risks of all-cause mortality and disease progression, in addition to
33 achieving low viral burden faster than their respective matched controls. Oral antiviral use
34 was also associated with a reduced need for oxygen therapy. To our knowledge, this is the

1 first real-world study exploring the inpatient use of oral antivirals during a pandemic wave
2 dominated by the SARS-CoV-2 Omicron BA.2 subvariant.

3

4 Based on the very limited studies on the safety and efficacy of oral antivirals in COVID-19
5 patients, current guidelines and the medical community are now prioritizing their distribution
6 to those who do not require supplemental oxygen, but who are at the highest risk of disease
7 progression, i.e. who will likely benefit the most from antivirals.^{4,11,25,26} Our study cohort
8 reflected such prescription pattern in real-world clinical practice; and provided real-world
9 evidence supporting their use in those at risk of progression to severe disease, namely the
10 elderly with multiple pre-existing comorbidities and who had not been fully vaccinated,
11 during a pandemic wave dominated by the Omicron variant. The significant risk reduction in
12 disease progression associated with both molnupiravir and nirmatrelvir/ritonavir was mainly
13 driven by a substantial reduction in mortality risk, which has been illustrated in respective
14 major clinical trials conducted prior to the Omicron wave (when the major circulating VOC
15 was Delta),^{27,28} and some recent studies of nirmatrelvir/ritonavir during an Omicron
16 surge.^{29,30} Despite an inpatient setting of the current study, our patient population who did not
17 require any supplemental oxygen at baseline was likely different from that of the MOVE-IN
18 trial, where the majority presented with moderate-to-severe COVID-19 and approximately
19 half of the patients were on oxygen therapy.³¹ Also, our molnupiravir users might not be
20 comparable to those of the MOVE-OUT trial, where the antiviral was initiated early to non-
21 hospitalized patients with mild-to-moderate COVID-19.²⁸ A secondary analysis of MOVE-
22 OUT trial has identified a reduced need for respiratory interventions among molnupiravir
23 users than those treated with placebo, including the patient subgroup who were hospitalized
24 after randomization.³² Notably, our results established a significant mortality benefit and
25 reduced disease progression (of increasing oxygen needs) among molnupiravir users who
26 were hospitalized and not requiring any supplemental oxygen on admission, whilst these
27 were not evident in the MOVE-IN trial when it was initiated at a later and more severe stage
28 of COVID-19.³¹

29

30 In terms of viral burden reduction, our patients managed to achieve low viral burden faster
31 with molnupiravir or nirmatrelvir/ritonavir use upon SARS-CoV-2 infection of the Omicron
32 variant, which added clinical support to the efficacy of oral antivirals demonstrated in
33 experimental studies.³³⁻³⁸ In recent studies based on previous VOC (including Delta), early
34 initiation of molnupiravir has been shown to promote clinical improvement and symptom

1 resolution in patients with mild-to-moderate COVID-19, in addition to accelerating viral
2 burden reduction, SARS-CoV-2 RNA clearance, and elimination of infectious virus.^{28,39-41}
3 The EPIC-HR trial was also conducted prior to the prevalence of Omicron variant, where
4 nirmatrelvir/ritonavir use was associated with significant viral burden reduction of Delta
5 variant in patients with mild-to-moderate COVID-19 compared to placebo.^{25,27} To the best of
6 our knowledge, this is one of the first clinical studies offering real-world evidence of oral
7 antiviral use on reducing viral burden among COVID-19 patients during a pandemic wave of
8 Omicron BA.2 subvariant. This is consistent with faster viral RNA clearance identified with
9 molnupiravir use in the latest clinical trial conducted among hospitalized patients with mild-
10 to-moderate COVID-19 of the Omicron variant.⁴² Meanwhile, results of our subgroup
11 analyses seemed to suggest a lack of significant benefits in younger patients and those who
12 had been fully vaccinated, which would add support to prioritize the prescription of oral
13 antivirals to the elderly and those with inadequate vaccination, who were also likely at a
14 higher risk of progression to severe COVID-19. Likewise, recent studies of
15 nirmatrelvir/ritonavir during an Omicron surge have suggested significant clinical and
16 mortality benefits in the elderly, yet insufficient evidence for younger patients.^{29,30}
17 Nevertheless, further research on the real-world effectiveness of oral antivirals in specific
18 patient populations is needed, as our results could be confounded by the limited sample size,
19 and hence the small number of events, in certain patient subgroups.

20
21 This territory-wide, retrospective cohort study of COVID-19 patients who did not initially
22 require supplemental oxygen suggested that initiating oral antivirals within 2 days of
23 admission was associated with significant risk reduction in all-cause mortality and disease
24 progression, and achieving low viral burden faster compared to non-use. Referring to the
25 medical records of hospitalized cases who were closely monitored, clinical outcomes and
26 procedures were systematically documented and analyzed. Medication adherence could also
27 be guaranteed in an inpatient setting compared to oral antiviral users in the community.
28 Nevertheless, several limitations of our study should be acknowledged. Firstly, we cannot
29 exclude the possibility of selection bias or confounding by indication in this observational
30 study, despite our population-based cohort was fully representative of the local COVID-19
31 patient population who did not require supplemental oxygen on admission. Besides, the
32 clinical profile of our patients who would be deemed at risk of progression to severe COVID-
33 19 might be different from those in the major trials of molnupiravir and nirmatrelvir/ritonavir,
34 for instance, their dominant risk factor was overweight or obesity,^{27,28} whilst ours was old age.

1 Moreover, since our study was retrospective, patients that received oral antivirals could be
2 those considered in more need for treatment than those that remained untreated, despite
3 balance on propensity score weighting of variables including those indicating severity.
4 Unfortunately, information on symptom onset date in most of the patients, oxygen saturation,
5 respiratory rate, and pulse rate that might have been appropriate indicators of illness severity
6 were unavailable for this retrospective study. Secondly, our results could potentially be
7 biased considering clinical contraindications by drug-drug interactions for
8 nirmatrelvir/ritonavir, or patient preferences to avoid molnupiravir due to concerns about
9 possible mutagenicity on fertility or pregnancy.⁴³ However, our analysis excluded patients
10 with drug contraindications to nirmatrelvir/ritonavir, and those with severe renal or liver
11 diseases for fair comparisons between oral antiviral users and matched controls. Thirdly,
12 since the Ct value was no longer adopted as one of the discharge criteria during our study
13 period, patients might have already been deemed clinically stable for discharge before
14 reaching the specific cutoff. Furthermore, the interpretation of our viral burden results could
15 be dependent on the efficiency of sampling, specimen type, and limited by the lack of clinical
16 data on viral infectiousness. While all hospitals shared the same standard care protocol for
17 COVID-19 patients, including discharge criteria, there was no clear and consistent
18 documentation in the electronic health records. As such, we caution that our LOS outcome
19 might be specific and not generalizable to other settings. Accordingly, further studies are
20 needed to confirm our findings on viral burden reduction and LOS associated with oral
21 antiviral use. Lastly, the generalizability of our findings could be undermined by an inpatient
22 setting of our cohort, and some of our subgroup analyses were likely underpowered due to
23 their small sample sizes (namely younger patients and those who were fully vaccinated).
24 Results from ongoing trials (namely PANORAMIC⁴⁴ and RECOVERY⁴⁵, NCT04746183,
25 NCT05195060, and NCT05011513) and observational studies are awaiting, and further
26 research is needed to explore the safety and effectiveness of oral antivirals in different patient
27 populations (especially by COVID-19 vaccination status and VOC), drug combinations, and
28 other healthcare settings such as nursing homes or residential care facilities.

29

30 As proposed by the medical and research community, logistics and distribution issues should
31 be adequately addressed by governments and the healthcare sector to meet ethical standards
32 and promote optimal and equitable access in the face of limited supplies, such as developing
33 an evidence-based scoring system or risk prediction tools to help physicians prioritizing the
34 distribution of oral antivirals to COVID-19 patients who would most likely benefit from them,

1 based on predicted efficacy and risk assessments.^{11,25,26} Notably, some unknown long-term
2 risks associated with molnupiravir use include possible carcinogenicity and teratogenicity, as
3 mutations have been observed in mammalian cells *in vitro*; and the risk of emergence of more
4 infectious and vaccine-resistant viral variants attributed to the genetic mutations induced.⁷⁻
5 ^{9,46-48} Moreover, concerns about the development of drug resistance to molnupiravir and
6 nirmatrelvir/ritonavir have been raised, especially considering the high mutation rates of
7 SARS-CoV-2 and potential selective pressure induced by an extensive use of antiviral
8 monotherapy.^{26,49} Active pharmacovigilance programs and sequencing of viral mutations are
9 essential to monitoring their long-term safety and effectiveness in different patient
10 populations and waves of COVID-19 pandemic.²⁶

11

12 In conclusion, this retrospective cohort study of hospitalized COVID-19 patients who did not
13 initially require supplemental oxygen suggested that early initiation of oral antivirals was
14 associated with significant risk reduction in all-cause mortality and disease progression, as
15 well as achieving low viral burden faster than non-use, during an epidemic of the SARS-
16 CoV-2 Omicron BA.2 subvariant. As both oral antivirals are currently indicated for non-
17 hospitalized COVID-19 patients who are at high risk of disease progression, ongoing
18 research will inform the safety and effectiveness of oral antivirals in specific patient
19 populations, drug combinations, and healthcare settings.

1 **Contributors**

2 The study was designed by CKHW, GML and BJC. CKHW, ICHA, EHYL and BJC had
3 access to the underlying data of the study. The underlying data were verified by CKHW,
4 ICHA and EHYL. Data analyses were done by CKHW and ICHA. CKHW and KTKL wrote
5 the first draft of the manuscript which was revised by GML and BJC. CKHW, GML and BJC
6 were responsible for the decision to submit for publication. All authors interpreted data,
7 provided critical review and revision of the text and approved the final version of the
8 manuscript.

9 10 **Data Sharing**

11 The clinical outcome data were extracted from the Hospital Authority database in Hong Kong
12 and vaccination records were extracted from the eSARS data provided by the Centre for
13 Health Protection. The data custodians (the Hospital Authority and the Department of Health
14 of Hong Kong SAR government) provided the underlying individual patient data to the
15 University of Hong Kong for the purpose of performing scientific research for the study.
16 Restrictions apply to the availability of these data, which were used under license for this
17 study. Authors must not transmit or release the Data, in whole or in part and in whatever form
18 or media, or any other parties or place outside Hong Kong; and fully comply with the duties
19 under the law relating to the protection of personal data including those under the Personal
20 Data (Privacy) Ordinance and its principles in all aspects.

21 22 **Declaration of interests**

23 BJC reports honoraria from AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer,
24 Roche and Sanofi Pasteur. BJC has provided scientific advice to Pfizer and AstraZeneca on
25 issues related to disease burden and vaccine effectiveness. He has not provided scientific
26 advice to either company related to COVID antiviral effectiveness, and he has not received
27 any funding from Pfizer or AstraZeneca for any research on antiviral effectiveness including
28 the current work. The authors report no other potential conflicts of interest.

29 30 **Funding**

31 This study was supported by the Health and Medical Research Fund (reference number:
32 COVID190210), Food and Health Bureau of the Hong Kong Government.

1 **References**

- 2
- 3 1. The U.S. Food and Drug Administration (FDA). Fact Sheet for Healthcare Providers:
4 Emergency Use Authorization for Lagevrio™ (molnupiravir). 2022/06/01 2022.
5 <https://www.fda.gov/media/155054/download>.
- 6 2. The U.S. Food and Drug Administration (FDA). Fact Sheet for Healthcare Providers:
7 Emergency Use Authorization for Paxlovid™. 2022/06/28 2022.
8 <https://www.fda.gov/media/155050/download>.
- 9 3. Infectious Diseases Society of America. IDSA Guidelines on the Treatment and
10 Management of Patients with COVID-19. 2022/06/10 2022.
11 <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>.
- 12 4. The National Institutes of Health. Therapeutic Management of Nonhospitalized
13 Adults With COVID-19. 2022/04/08 2022.
14 [https://www.covid19treatmentguidelines.nih.gov/management/clinical-
15 management/nonhospitalized-adults--therapeutic-management/](https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/).
- 16 5. Schöning V, Kern C, Chaccour C, Hammann F. Effectiveness of Antiviral Therapy in
17 Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study.
18 *Frontiers in Pharmacology* 2022; **13**: 816429.
- 19 6. Singh AK, Singh A, Singh R, Misra A. An updated practical guideline on use of
20 molnupiravir and comparison with agents having emergency use authorization for treatment
21 of COVID-19. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 2022; **16**(2):
22 102396.
- 23 7. Tian L, Pang Z, Li M, et al. Molnupiravir and Its Antiviral Activity Against COVID-
24 19. *Frontiers in Immunology* 2022; **13**: 855496.
- 25 8. Brophy JM. Molnupiravir's authorisation was premature. *BMJ* 2022; **376**: o443.
- 26 9. Dyer O. Covid-19: FDA expert panel recommends authorising molnupiravir but also
27 voices concerns. *BMJ* 2021; **375**: n2984.
- 28 10. Hama R. Imbalance in baseline characteristics in molnupiravir trials. *BMJ* 2022; **377**:
29 o977.
- 30 11. Dal-Ré R, Becker SL, Bottieau E, Holm S. Availability of oral antivirals against
31 SARS-CoV-2 infection and the requirement for an ethical prescribing approach. *The Lancet
32 Infectious Diseases* 2022. doi:10.1016/S1473-3099(22)00119-0
- 33 12. Wong CKH, Wan EYF, Luo S, et al. Clinical outcomes of different therapeutic
34 options for COVID-19 in two Chinese case cohorts: A propensity-score analysis.
35 *eClinicalMedicine* 2021; **32**: 100743.
- 36 13. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of two and three doses
37 of BNT162b2 and CoronaVac against COVID-19 in Hong Kong. *medRxiv* 2022. doi:
38 10.1101/2022.03.22.22272769
- 39 14. Liverpool Drug Interactions Group. Interactions with Outpatient Medicines &
40 Nirmatrelvir/ritonavir (NMV/r). 2022/06/08 2022. <https://www.covid19-druginteractions.org/>.

- 1 15. The Government of the Hong Kong Special Administrative Region. LCQ7:
2 Introduction of new drugs for treating Coronavirus Disease 2019. 2022/02/23 2022.
3 <https://www.info.gov.hk/gia/general/202202/23/P2022022300303.htm>.
- 4 16. The Government of the Hong Kong Special Administrative Region. First shipment of
5 COVID-19 oral drug Paxlovid distributed to HA for application (with photos). 2022/03/15
6 2022. <https://www.info.gov.hk/gia/general/202203/15/P2022031500280.htm>.
- 7 17. Gupta S, Wang W, Hayek SS, et al. Association Between Early Treatment With
8 Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. *JAMA Internal*
9 *Medicine* 2021; **181**(1): 41-51.
- 10 18. Monedero P, Gea A, Castro P, et al. Early corticosteroids are associated with lower
11 mortality in critically ill patients with COVID-19: a cohort study. *Critical Care* 2021; **25**(1):
12 2.
- 13 19. Renoux C, Azoulay L, Suissa S. Biases in evaluating the safety and effectiveness of
14 drugs for covid-19: designing real-world evidence studies. *American Journal of*
15 *Epidemiology* 2021; **190**(8): 1452-6.
- 16 20. Wong CKH, Lau KTK, Au ICH, Xiong X, Lau EHY, Cowling BJ. Clinical
17 Improvement, Outcomes, Antiviral Activity, and Costs Associated With Early Treatment
18 With Remdesivir for Patients With Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis*
19 2022; **74**(8): 1450-8.
- 20 21. The Government of the Hong Kong Special Administrative Region. Government
21 announces latest criteria for discharge from isolation and home quarantine. 2022/02/26 2022.
22 <https://www.info.gov.hk/gia/general/202202/26/P2022022600750.htm>.
- 23 22. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues
24 and guidance for practice. *Stat Med* 2011; **30**(4): 377-99.
- 25 23. Leyrat C, Seaman SR, White IR, et al. Propensity score analysis with partially
26 observed covariates: How should multiple imputation be used? *Stat Methods Med Res* 2019;
27 **28**(1): 3-19.
- 28 24. Austin PC. Some methods of propensity-score matching had superior performance to
29 others: results of an empirical investigation and Monte Carlo simulations. *Biom J* 2009; **51**(1):
30 171-84.
- 31 25. Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and Nirmatrelvir-Ritonavir:
32 Oral COVID Antiviral Drugs. *Clinical Infectious Diseases* 2022: ciac180.
- 33 26. World Health Organization. Therapeutics and COVID-19: living guideline.
34 2022/04/22 2022. [https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-](https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.2)
35 [2022.2](https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.2).
- 36 27. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk,
37 Nonhospitalized Adults with Covid-19. *New England Journal of Medicine* 2022; **386**(15):
38 1397-408.

- 1 28. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral
2 Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med* 2022; **386**(6): 509-20.
- 3 29. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in Reducing
4 Severe COVID-19 and Mortality in High Risk Patients. *Clinical Infectious Diseases* 2022;
5 ciac443.
- 6 30. Arbel R, Sagy YW, Hoshen M, et al. Oral Nirmatrelvir and Severe Covid-19
7 Outcomes During the Omicron Surge. *Research Square* 2022. doi:10.21203/rs.3.rs-
8 1705061/v1
- 9 31. Arribas José R, Bhagani S, Lobo Suzana M, et al. Randomized Trial of Molnupiravir
10 or Placebo in Patients Hospitalized with Covid-19. *NEJM Evidence* 2022; **1**(2):
11 EVIDoa2100044.
- 12 32. Johnson MG, Puenpatom A, Moncada PA, et al. Effect of Molnupiravir on
13 Biomarkers, Respiratory Interventions, and Medical Services in COVID-19. *Annals of*
14 *Internal Medicine* 2022. doi:10.7326/M22-0729
- 15 33. Bojkova D, Widera M, Ciesek S, Wass MN, Michaelis M, Cinatl J. Reduced
16 interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta
17 variant of SARS-CoV-2 isolates. *Cell Research* 2022; **32**(3): 319-21.
- 18 34. Li P, Wang Y, Lavrijsen M, et al. SARS-CoV-2 Omicron variant is highly sensitive to
19 molnupiravir, nirmatrelvir, and the combination. *Cell Research* 2022; **32**(3): 322-4.
- 20 35. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antibodies and Antiviral
21 Drugs against Covid-19 Omicron Variant. *New England Journal of Medicine* 2022; **386**(10):
22 995-8.
- 23 36. Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir
24 remain active against SARS-CoV-2 Omicron and other variants of concern. *Antiviral*
25 *Research* 2022; **198**: 105252.
- 26 37. Ullrich S, Ekanayake KB, Otting G, Nitsche C. Main protease mutants of SARS-
27 CoV-2 variants remain susceptible to nirmatrelvir. *Bioorganic & Medicinal Chemistry*
28 *Letters* 2022; **62**: 128629.
- 29 38. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antiviral Agents against
30 the SARS-CoV-2 Omicron Subvariant BA.2. *New England Journal of Medicine* 2022;
31 **386**(15): 1475-7.
- 32 39. Hetero. Hetero Announces Interim Clinical Results from Phase III Clinical Trials of
33 Molnupiravir conducted in India. Hyderabad, India: Hetero; 2021.
- 34 40. Fischer William A, Eron Joseph J, Holman W, et al. A phase 2a clinical trial of
35 molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance
36 and elimination of infectious virus. *Science Translational Medicine* 2022; **14**(628): eabl7430.
- 37 41. Merck. Merck and Ridgeback to Present Data Demonstrating That Treatment With
38 LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious
39 SARS-CoV-2 Than Placebo. 2022/04/01 2022. <https://www.merck.com/news/merck-and->

- 1 [ridgeback-to-present-data-demonstrating-that-treatment-with-lagevrio-molnupiravir-was-](#)
2 [associated-with-more-rapid-elimination-of-infectious-sars-cov-2-than-placebo/](#).
- 3 42. Zou R, Peng L, Shu D, et al. Antiviral Efficacy and Safety of Molnupiravir Against
4 Omicron Variant Infection: A Randomized Controlled Clinical Trial. *Front. Pharmacol.* 2022;
5 **13**:939573.
- 6 43. Soriano V, de-Mendoza C, Edagwa B, et al. Oral antivirals for the prevention and
7 treatment of SARS-CoV-2 infection. *AIDS Rev* 2022; **24**(1): 41-9.
- 8 44. University of Oxford. PANORAMIC (Platform Adaptive trial of NOvel antiViRals for
9 eArly treatMent of COVID-19 In the Community). 2022. <https://www.panoramictrial.org/>
10 (accessed 2022/06/08).
- 11 45. Nuffield Department of Population Health. RECOVERY (Randomised Evaluation of
12 COVID-19 Therapy). 2022. <https://www.recoverytrial.net/> (accessed 2022/06/08).
- 13 46. Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic
14 review of literature. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* 2021;
15 **15**(6): 102329.
- 16 47. Waters MD, Warren S, Hughes C, Lewis P, Zhang F. Human genetic risk of treatment
17 with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of
18 molnupiravir. *Environmental and Molecular Mutagenesis* 2022; **63**(1): 37-63.
- 19 48. Zhou S, Hill CS, Sarkar S, et al. β -d-N4-hydroxycytidine Inhibits SARS-CoV-2
20 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. *The Journal of*
21 *Infectious Diseases* 2021; **224**(3): 415-9.
- 22 49. Mótyán JA, Mahdi M, Hoffka G, Tózsér J. Potential Resistance of SARS-CoV-2
23 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease.
24 *International Journal of Molecular Sciences* 2022; **23**(7): 3507.

Figure 1. Identification of molnupiravir users, nirmatrelvir/ritonavir users, and their matched controls among patients hospitalized with COVID-19 not requiring oxygen therapy from 26th February 2022 to 26th April 2022 in Hong Kong




Figure 2. Cumulative incidence plots of (a) all-cause mortality, (b) composite progression outcome, and (c) lower viral burden for molnupiravir users versus their matched controls, and (a) all-cause mortality, (b) composite progression outcome, and (c) lower viral burden for nirmatrelvir/ritonavir users versus the matched controls





Figure 3. Comparison of disease status at days 3, 7, 14, 21, and 28 after the index date (hospital admission) a) between molnupiravir users and their matched controls, and b) between nirmatrelvir/ritonavir users and their matched control






Table 1. Baseline characteristics of inpatients with COVID-19 in (a) molnupiravir and respective matched control groups, and (b) nirmatrelvir-ritonavir and respective matched control groups before 1:1 propensity score matching

Baseline characteristics	Before 1:1 propensity score matching						After 1:1 propensity score matching			
	Molnupiravir (n=1,880)		Nirmatrelvir/ ritonavir (n=924)		Control (n=14,810)		Molnupiravir vs Control	Nirmatrelvir/ ritonavir vs Control	Molnupiravir vs Control	Nirmatrelvir/ ritonavir vs Control
	N / Mean	% / SD	N / Mean	% / SD	N / Mean	% / SD	SMD	SMD	SMD	SMD
Age, years†	80.8	13.0	77.2	14.1	74.3	18.7	0.36	0.16	0.04	0.05
18-40	27	(1.4%)	29	(3.1%)	1,313	(8.9%)				
40-65	207	(11.0%)	132	(14.3%)	2,474	(16.7%)	0.40	0.26	0.10	0.07
>65	1,646	(87.6%)	763	(82.6%)	11,023	(74.4%)				
Sex										
Male	925	(49.2%)	462	(50.0%)	7,500	(50.6%)	0.03	0.01	0.02	0.02
Female	955	(50.8%)	462	(50.0%)	7,310	(49.4%)				
Regions										
Hong Kong Island	502	(26.7%)	187	(20.2%)	2,297	(15.5%)				
Kowloon	607	(32.3%)	288	(31.2%)	4,978	(33.6%)	0.29	0.13	0.05	0.07
New Territories	770	(41.0%)	446	(48.3%)	7,511	(50.7%)				
Others	1	(0.1%)	3	(0.3%)	24	(0.2%)				
Nursing home residents	579	(30.8%)	130	(14.1%)	5,003	(33.8%)	0.06	0.47	0.03	0.01
Symptom onset date reported	1,008	(53.6%)	404	(43.7%)	5,786	(39.1%)	0.29	0.09	0.01	0.03
Time from symptom onset to hospitalization, days										
0	394	(39.1%)	160	(39.6%)	2,050	(35.4%)	0.08	0.09	0.01	0.01
1-5	614	(60.9%)	244	(60.4%)	3,736	(64.6%)				
Nosocomial infection	45	(2.4%)	30	(3.2%)	968	(6.5%)	0.20	0.15	0.02	0.02
Time of admission										
February/March 2022	1,588	(84.5%)	626	(67.8%)	12,963	(87.5%)	0.09	0.13	0.06	0.01
April 2022	292	(15.5%)	298	(32.3%)	1,847	(12.5%)				

Charlson's Index†	5.8	1.9	5.1	1.7	5.0	2.4	0.33	0.03	0.01	0.02
1-4	459	(24.4%)	312	(33.8%)	5,312	(35.9%)				
5-6	878	(46.7%)	465	(50.3%)	5,951	(40.2%)	0.25	0.24	0.06	0.09
7-14	543	(28.9%)	147	(15.9%)	3,547	(24.0%)				
Previous SARS-CoV-2 infection	0	(0.0%)	0	(0.0%)	3	(0.0%)	0.02	0.02	NA	NA
Fully vaccinated*	116	(6.2%)	97	(10.5%)	1,328	(9.0%)	0.11	0.05	0.00	0.03
Concomitant treatments initiated at admission										
Antibiotics	222	(11.8%)	158	(17.1%)	1,785	(12.1%)	0.01	0.14	0.00	0.00
Immunomodulators	260	(13.8%)	106	(11.5%)	3,258	(22.0%)	0.21	0.28	0.04	0.01
Dexamethasone	240	(12.8%)	87	(9.4%)	2,989	(20.2%)	0.20	0.31	0.04	0.00
Other systemic steroid	18	(1.0%)	22	(2.4%)	244	(1.6%)	0.06	0.05	0.00	0.04
Interferon-β-1b	10	(0.5%)	4	(0.4%)	195	(1.3%)	0.08	0.10	0.04	0.00
Baricitinib	0	(0.0%)	4	(0.4%)	29	(0.2%)	0.06	0.04	0.06	0.02
Tocilizumab	0	(0.0%)	0	(0.0%)	8	(0.1%)	0.03	0.03	0.03	NA
Laboratory parameters at admission†										
Cycle threshold value, cycle	22.3	6.1	23.2	7.0	24.3	7.4	0.28	0.15	0.08	0.12
<20	795	(42.3%)	355	(38.4%)	3,904	(26.4%)				
20-<30	846	(45.0%)	389	(42.1%)	7,753	(52.4%)				
30-<35	141	(7.5%)	117	(12.7%)	1,846	(12.5%)	0.36	0.27	0.07	0.05
≥35	98	(5.2%)	63	(6.8%)	1,307	(8.8%)				
Lactate dehydrogenase, U/L	262.0	193.9	254.8	127.8	278.0	220.0	0.07	0.11	0.02	0.00
C-reactive protein, mg/L	46.3	50.3	44.2	49.9	71.8	67.6	0.39	0.41	0.06	0.05
Lymphocyte, ×10 ⁹ /L	1.2	3.2	1.2	2.1	1.1	1.3	0.06	0.05	0.00	0.04

Notes: NA = not applicable; SD = standard deviation; SMD = standardized mean difference

* Fully vaccinated patients were defined as those with at least 2 doses of Comirnaty or 3 doses of CoronaVac.

† Age, Charlson Comorbidity Index, time from symptom onset to hospitalization, and laboratory parameters at admission are presented in mean ± SD.

Table 2. Hazard ratios of clinical and virologic outcomes for molnupiravir users versus their matched controls, and differences in hospital length of stay between the groups amongst discharged survivors

Outcomes	Molnupiravir (N=1,856)						Control (N=1,856)					Molnupiravir vs Control		
	Cumulative incidence		Crude incidence rate (Events / 10,000 person-days)				Cumulative incidence		Crude incidence rate (Events / 10,000 person-days)			HR†	95% CI	P-value
	New events	Rate	Estimate	95% CI	Person-days	New events	Rate	Estimate	95% CI	Person-days				
All-cause mortality	150	8.1%	19.98	(16.91, 23.45)	75,065	295	15.9%	38.07	(33.85, 42.67)	77,495	0.48	(0.40, 0.59)	<0.0001	
Invasive mechanical ventilation	7	0.4%	0.93	(0.38, 1.92)	74,982	17	0.9%	2.20	(1.28, 3.52)	77,343	0.42	(0.17, 1.01)	0.052	
Intensive care unit admission	1	0.1%	0.13	(0.00, 0.74)	75,047	2	0.1%	0.26	(0.03, 0.93)	77,462	NA	NA	NA	
Need for oxygen therapy	192	11.8%	31.76	(27.43, 36.59)	60,447	260	16.4%	44.35	(39.12, 50.08)	58,631	0.69	(0.57, 0.83)	0.00011	
Composite progression outcome*	306	16.5%	44.49	(39.64, 49.76)	68,782	481	25.9%	69.87	(63.76, 76.40)	68,846	0.60	(0.52, 0.69)	<0.0001	
Lower viral burden	274	17.0%	145.79	(129.04, 164.12)	18,794	209	12.9%	100.24	(87.11, 114.79)	20,850	1.38	(1.15, 1.64)	0.00046	
			Mean	95% CI				Mean	95% CI		Diff	95% CI	P-value	
Hospital length of stay, days			10.82	(10.41, 11.23)				11.50	(11.03, 11.98)		-0.68	(-1.31, -0.06)	0.033	

Notes: CI = confidence interval; Diff = difference; HR = hazard ratio; NA = not applicable

HR were estimated only when the number of events in both groups were more than or equal to 2.

† HR >1 (or <1) indicates molnupiravir users had higher (lower) risk of outcome or quick (slower) time to lower viral burden compared to the matched control group.

* Composite progression outcome includes all-cause mortality, invasive mechanical ventilation, intensive care unit admission, and need for oxygen therapy.

Table 3. Hazard ratios of clinical and virologic outcomes, and hospital length of stay for nirmatrelvir/ritonavir users versus matched controls, and differences in hospital length of stay between the groups amongst discharged survivors

Outcomes	Nirmatrelvir/ritonavir (N=890)					Control (N=890)					Nirmatrelvir/ritonavir vs Control		
	Cumulative incidence		Crude incidence rate (Events / 10,000 person-days)			Cumulative incidence		Crude incidence rate (Events / 10,000 person-days)			HR†	95% CI	P-value
	New events	Rate	Estimate	95% CI	Person-days	New events	Rate	Estimate	95% CI	Person-days			
All-cause mortality	32	3.6%	10.28	(7.03, 14.51)	31,123	92	10.3%	26.47	(21.34, 32.46)	34,762	0.34	(0.23, 0.50)	<0.0001
Invasive mechanical ventilation	6	0.7%	1.93	(0.71, 4.21)	31,035	6	0.7%	1.73	(0.63, 3.76)	34,745	0.97	(0.31, 3.03)	0.96
Intensive care unit admission	0	0.0%	0.00	NA	31,123	1	0.1%	0.29	(0.01, 1.60)	34,750	NA	NA	NA
Need for oxygen therapy	79	10.1%	31.53	(24.96, 39.29)	25,057	102	13.6%	38.24	(31.18, 46.42)	26,676	0.73	(0.54, 0.97)	0.032
Composite progression outcome*	101	11.3%	35.04	(28.54, 42.57)	28,827	173	19.4%	54.98	(47.09, 63.81)	31,468	0.57	(0.45, 0.72)	<0.0001
Lower viral burden	136	19.0%	187.10	(156.97, 221.31)	7,269	105	14.6%	124.44	(101.78, 150.64)	8,438	1.38	(1.07, 1.79)	0.013
Hospital length of stay, days			Mean	95% CI				Mean	95% CI		Diff	95% CI	P-value
			9.59	(9.06, 10.12)				10.02	(9.35, 10.69)		-0.43	(-1.29, 0.42)	0.32

Notes: CI = confidence interval; Diff = difference; HR = hazard ratio; NA = not applicable

HR were estimated only when the number of events in both groups were more than or equal to 2.

† HR >1 (or <1) indicates nirmatrelvir/ritonavir users had higher (lower) risk of outcome or quick (slower) time to lower viral burden compared to the matched control group.

* Composite progression outcome includes all-cause mortality, invasive mechanical ventilation, intensive care unit admission, and need for oxygen therapy.